Global Cerebral Vasospasm Market Size, Share, Forecast Report, 2020-2027

The global cerebral vasospasm market is expected to register an approximate CAGR of 5.4% during the forecast period. The narrowing of cerebral arteries is termed as cerebral vasospasm. Cerebral vasospasm is most commonly observed in patients who survive subarachnoid hemorrhage. Narrowing of cerebral artery leads to cerebral ischemia and then death. Increasing prevalence of subarachnoid hemorrhage and a rise in the prevalence of traumatic brain injury is the key factor driving the growth of the market. According to the Centers for Disease Control and Prevention 2017, 30% of the total injury deaths are due to traumatic brain injury in the US. Other factors contributing to the growth of the market are increasing hypertension among the population, rising adoption of smoking, changing lifestyle, growing geriatric population, increasing prevalence of bleeding disorders, rising use of blood thinners and the introduction of technologically advanced treatments.

However, factors such as high cost associated with treatment, risks associated with drugs and medication and a shortage of skilled professionals are expected to hinder the market growth during the forecast period.

Segmentation

The global cerebral vasospasm market is segmented on the basis of diagnosis, treatment, and end-user. The global cerebral vasospasm market, by diagnosis, is segmented into CT scan, computed tomography angiography (CTA), digital subtraction angiography (DSA), magnetic resonance angiography (MRA), transcranial Doppler (TCD), and others. The treatment segment is segmented into nimodipine, triple-h therapy, balloon angioplasty, vasopressors, inotropes, thrombolytic agents and anti-inflammatory agents. On the basis of end-users, the global cerebral vasospasm market is segmented into hospitals and clinics, ambulatory surgical centers, trauma centers, emergency departments and others.
Key players

Some of the key players in this market are Headsense Medical Ltd (Israel), B. Braun Melsungen AG (Germany), Minnetronix, Inc (US), Bristol-Myers Squibb Company (US), Boehringer Ingelheim GmbH (Germany) and H. Lundbeck A/S (Denmark), Actelion Pharmaceuticals Ltd, GE Healthcare, Edge Therapeutics, Inc, SIEMENS AG, Koninklijke Philips N.V, and others.

Global Cerebral Vasospasm Market, by Diagnosis

• CT Scan
• Computed Tomography Angiography (CTA)
• Digital Subtraction Angiography (DSA)
• Magnetic Resonance Angiography (MRA)
• Transcranial Doppler (TCD)

Global Cerebral Vasospasm Market, by Treatment

• Nimodipine
• Triple-H therapy
• Balloon Angioplasty
• Vasopressors
• Inotropes
• Thrombolytic Agents
• Anti-inflammatory Agents

Global Cerebral Vasospasm Market, by End-Users

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Trauma Centers
• Emergency Departments
• Others